Risk factors for severe infection and mortality In patients with <scp>COVID</scp>‐19 in patients with multiple myeloma and <scp>AL</scp> amyloidosis
Matthew Ho(Mayo Clinic), Shaji Kumar(Mayo Clinic), Jeremy T. Larsen(City of Hope), David Dingli, Asher Chanan‐Khan(WinnMed), Francis K. Buadi, Morie A. Gertz(Medical University of South Carolina), Taimur Sher(Mayo Clinic in Florida), Nelson Leung(WinnMed), Robert A. Kyle(Mayo Clinic), Ronald S. Go(Mayo Clinic), Prashant Kapoor, Amie Fonder, Moritz Binder(Mayo Clinic in Arizona), Yi L. Hwa, Sikander Ailawadhi(Jacksonville College), Rahma Warsame, S. Vincent Rajkumar(WinnMed), Wilson I. Gonsalves(Mayo Clinic in Arizona), Taxiarchis Kourelis(Mayo Clinic in Arizona), Saurabh Zanwar(Mayo Clinic), Martha Q. Lacy(Mayo Clinic), Eli Muchtar(Mayo Clinic), Yi Lin, Vivek Roy(Jacksonville College), Suzanne R. Hayman, Miriam Hobbs, Angela Dispenzieri(Mayo Clinic), Leif Bergsagel(WinnMed), Rafaël Fonseca(Mayo Clinic in Arizona)
Cited by 23
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k